Researchers from Boston-based Dana Farber Cancer Institute, New York City-based Memorial Sloan Kettering Cancer Center, LMU University Hospital in Munich, Germany, and Davidoff Cancer Center in Tel Aviv, Israel, collaborated on the study.
They analyzed 18 clinical trials and 28 real-world studies from three databases — Medline, Embase and CINAHL — for non-relapse related deaths in 7,604 lymphoma and multiple myeloma patients up to March, according to the study.
Of 574 non-relapse-related deaths, 50.9% were attributed to infections after patients received CAR-T immunotherapy. Only 11.5% were attributed to CAR-T immunotherapy-specific side effects.
Other malignancies and cardiovascular or respiratory events were least attributed to non-relapse-related deaths at 7.8% and 7.3%, respectively.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
